These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 9708926)

  • 1. Flow cytometric DNA analysis and p53 protein expression show a good correlation with histologic findings in patients with Barrett's esophagus.
    Giménez A; Minguela A; Parrilla P; Bermejo J; Pérez D; Molina J; García AM; Ortiz MA; Alvarez R; de Haro LM
    Cancer; 1998 Aug; 83(4):641-51. PubMed ID: 9708926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA ploidy status and proliferative activity as markers of malignant potential in Barrett's esophagus: flow cytometric study using routinely paraffin-embedded tissue.
    Giménez A; Minguela A; de Haro LM; Parrilla P; Bermejo J; Pérez D; García AM; Ortiz MA; Molina J; Alvarez R
    World J Surg; 2000 Jan; 24(1):72-7. PubMed ID: 10594207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of genetic changes in Barrett's adenocarcinoma and Barrett's esophagus by DNA in situ hybridization and immunohistochemistry.
    Krishnadath KK; Tilanus HW; Alers JC; Mulder AH; van Dekken H
    Cytometry; 1994 Feb; 15(2):176-84. PubMed ID: 8168405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
    Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
    Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential application of p53 as an intermediate biomarker in Barrett's esophagus.
    Jones DR; Davidson AG; Summers CL; Murray GF; Quinlan DC
    Ann Thorac Surg; 1994 Mar; 57(3):598-603. PubMed ID: 8147627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-phosphorylated histone H3 expression in Barrett's esophagus, low-grade dysplasia, high-grade dysplasia, and adenocarcinoma.
    Goodarzi M; Correa AM; Ajani JA; Swisher SG; Hofstetter WL; Guha S; Deavers MT; Rashid A; Maru DM
    Mod Pathol; 2009 Dec; 22(12):1612-21. PubMed ID: 19734842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Barrett esophagus with dysplasia. Flow cytometric DNA analysis of routine, paraffin-embedded mucosal biopsies.
    Montgomery EA; Hartmann DP; Carr NJ; Holterman DA; Sobin LH; Azumi N
    Am J Clin Pathol; 1996 Sep; 106(3):298-304. PubMed ID: 8816585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crypt dysplasia with surface maturation: a clinical, pathologic, and molecular study of a Barrett's esophagus cohort.
    Lomo LC; Blount PL; Sanchez CA; Li X; Galipeau PC; Cowan DS; Ayub K; Rabinovitch PS; Reid BJ; Odze RD
    Am J Surg Pathol; 2006 Apr; 30(4):423-35. PubMed ID: 16625087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The value of p53 and Ki67 as markers for tumour progression in the Barrett's dysplasia-carcinoma sequence.
    Polkowski W; van Lanschot JJ; Ten Kate FJ; Baak JP; Tytgat GN; Obertop H; Voorn WJ; Offerhaus GJ
    Surg Oncol; 1995 Jun; 4(3):163-71. PubMed ID: 7582189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Does the criterium of positivity for the immunohistochemical analysis of p53 in the confirmation of Barrett's dysplasia make any difference?].
    Lopes CV; Pereira-Lima JC; Hartmann AA; Tonelotto E; Salgado K
    Arq Gastroenterol; 2005; 42(4):233-8. PubMed ID: 16444378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Qualitative mapping of Barrett's metaplasia: a prerequisite for intervention trials.
    Eisen GM; Montgomery EA; Azumi N; Hartmann DP; Bhargava P; Lippman M; Benjamin SB
    Gastrointest Endosc; 1999 Dec; 50(6):814-8. PubMed ID: 10570342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 protein accumulation in Barrett's metaplasia, dysplasia, and carcinoma: a follow-up study.
    Younes M; Lebovitz RM; Lechago LV; Lechago J
    Gastroenterology; 1993 Dec; 105(6):1637-42. PubMed ID: 8253340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic significance of nuclear p53 expression in the surveillance of Barrett's esophagus--a longitudinal study.
    Klump B; Hsieh CJ; Holzmann K; Borchard F; Gaco V; Greschniok A; Eckardt VF; Bettendorf U; Gregor M; Porschen R
    Z Gastroenterol; 1999 Oct; 37(10):1005-11. PubMed ID: 10549095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) and p53 tumor suppressor in dysplastic progression and adenocarcinoma in Barrett esophagus.
    Hanas JS; Lerner MR; Lightfoot SA; Raczkowski C; Kastens DJ; Brackett DJ; Postier RG
    Cancer; 1999 Sep; 86(5):756-63. PubMed ID: 10463972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry.
    Ramel S; Reid BJ; Sanchez CA; Blount PL; Levine DS; Neshat K; Haggitt RC; Dean PJ; Thor K; Rabinovitch PS
    Gastroenterology; 1992 Apr; 102(4 Pt 1):1220-8. PubMed ID: 1551529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Barrett's esophagus. Correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma.
    Reid BJ; Haggitt RC; Rubin CE; Rabinovitch PS
    Gastroenterology; 1987 Jul; 93(1):1-11. PubMed ID: 3582897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population-based study reveals new risk-stratification biomarker panel for Barrett's esophagus.
    Bird-Lieberman EL; Dunn JM; Coleman HG; Lao-Sirieix P; Oukrif D; Moore CE; Varghese S; Johnston BT; Arthur K; McManus DT; Novelli MR; O'Donovan M; Cardwell CR; Lovat LB; Murray LJ; Fitzgerald RC
    Gastroenterology; 2012 Oct; 143(4):927-35.e3. PubMed ID: 22771507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cdx2 expression and its promoter methylation during metaplasia-dysplasia-carcinoma sequence in Barrett's esophagus.
    Makita K; Kitazawa R; Semba S; Fujiishi K; Nakagawa M; Haraguchi R; Kitazawa S
    World J Gastroenterol; 2013 Jan; 19(4):536-41. PubMed ID: 23382633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical study of p53, c-erbB-2, and PCNA in barrett's esophagus with dysplasia and adenocarcinoma arising from experimental acid or alkaline reflux model.
    Kawaura Y; Tatsuzawa Y; Wakabayashi T; Ikeda N; Matsuda M; Nishihara S
    J Gastroenterol; 2001 Sep; 36(9):595-600. PubMed ID: 11578062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological characteristics of human epidermal growth factor receptor 2-positive Barrett's adenocarcinoma.
    Tanaka T; Fujimura A; Ichimura K; Yanai H; Sato Y; Takata K; Okada H; Kawano S; Tanabe S; Yoshino T
    World J Gastroenterol; 2012 Nov; 18(43):6263-8. PubMed ID: 23180947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.